Invokana Monotherapy Promising for T2D Control
LAS VEGAS (MedPage Today) -- The SGLT2 inhibitor canagliflozin (Invokana) may be effective as monotherapy in type 2 diabetes patients who fail to control their disease with diet and exercise, researchers said here.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Nutrition | SGLT2 Inhibitors | Sports Medicine